2025 GOLF TOURNAMENT IS FULL!
TOURNAMENT OF CHAMPIONS
Registration soon to open for the 2025 Zachary NF1 Golf Tournament
Our golf event fills-up quickly every year.
For 14 years, the Zachary NF Research Fund has hosted an annual golf tournament. All proceeds are donated directly to the University of Minnesota’s NF and cancer research lab.
Join us for a fun day golfing at Oak Glen Golf Club! We have a new course and date this year, it will be July 28, 2025 at Oak Glen Golf Club in Stillwater, MN. Don’t want to golf but still want to attend? Click the button “Dinner Only”. More details to come soon..
WHAT WE DO
We Raise Money To Help Find a Cure For
Neurofibromatosis Type 1 (NF1).
All proceeds are donated to the University of Minnesota’s NF Research Lab. The Researchers use these donations to support ground breaking research for neurofibromatosis and cancer treatments.
Neurofibromatosis
What is it?
Neurofibromatosis Type 1 (NF1) is a genetic disorder that causes tumors to grow on nerve tissue, in the brain, and in other parts of the body. Complications range from benign tumors to severe neurological deficits and malignant, life threatening cancer. There is no cure, and treatments are limited.
The frequency of NF1 is estimated to be 1 out of every 2,800 people. That means that the state of Minnesota alone has about 1,800 people with NF1.
A recent thorough study showed that the lifetime risk of cancer for NF1 patients is ~60%. The risk of cancer in NF1 is ~25% by age 30 and ~39% by age 50 (Uusitalo et al, Journal of Clinical Oncology, 2016)
ABOUT
Who We Are
As a translational neuro-oncology program, the University of Minnesota’s Brain Tumor Program accelerates the flow of information from basic science to the discovery of safer and more effective therapies for nervous system tumors.
This "bench-to-bedside" approach is made possible by the collaboration of strong, multidisciplinary teams who work towards a common goal - curing nervous system tumors using safer & more effective therapies.
Drs. Chris Moertel, Robert Galvin, Kyle Williams, and David Largaespada are two MDs and two PhDs (respectively) who work together on NF1 related tumors.
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
● Prevent Benign Tumors: Stop benign tumors from forming.
● Shrink Tumors: Reduce benign tumor size & prevent from becoming malignant.
● Develop Therapies: Create new & effective treatments for malignant tumors
Our Supporters
"CatSci's purpose is to get new medicines into the hands of patients in need and partnering the game changing siRNA drug development potential at Argonaute is a collaboration we are very excited about. Together we are exploring solutions for the manufacture of high-quality siRNA drug substance to enable robust preclinical studies and at scale for clinical trials." - Dr Ross Burn (CEO, CatSci)
“Our businesses interact seamlessly to ensure IP generation and business objectives are robust, enforceable and value generating.” - Rob Docherty PhD EPA MBA (Director, Symbiosis IP)
“At Carbometrics we specialise in the synthesis and bioconjugation of synthetic molecular recognition agents. Our collaboration with Argonaute is an excellent fusion of competencies and an exciting opportunity for us to use our chemistry expertise to augment what is already a paradigm shifting siRNA platform to create revolutionary therapeutics” - Andy Chapman (CEO and Co-founder, Carbometrics)
TOURNAMENT OF CHAMPIONS
Registration is full for 2024
Our golf event fills-up quickly every year.
Join us for a fun day golfing at Oak Glen Golf Club! We have a new course and date this year, it will be July 28, 2025 at Oak Glen Golf Club in Stillwater, MN. More details to come soon..
BLOGS
Our Latest Blogs & Articles
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s,
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s,
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s,
Join The Fight Against NF1
& Cancer
